Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2006-12-07
- Last Posted Date
- 2017-09-18
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 1206
- Registration Number
- NCT00408408
- Locations
- 🇺🇸
Iredell Memorial Hospital, Statesville, North Carolina, United States
🇺🇸Hattiesburg Clinic, PA at Forrest General, Hattiesburg, Mississippi, United States
🇺🇸Cancer Care Center, Incorporated, Salem, Ohio, United States
Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery
- Conditions
- Stage IA Breast CancerStage II Breast CancerStage IIIC Breast CancerStage IB Breast CancerStage IIIA Breast CancerHER2-positive Breast CancerStage IV Breast CancerEstrogen Receptor-positive Breast CancerStage IIIB Breast Cancer
- Interventions
- Drug: doxorubicin hydrochlorideDrug: cyclophosphamideBiological: filgrastimDrug: paclitaxel albumin-stabilized nanoparticle formulationBiological: trastuzumabOther: laboratory biomarker analysisProcedure: quality-of-life assessment
- First Posted Date
- 2006-12-05
- Last Posted Date
- 2017-08-31
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 60
- Registration Number
- NCT00407888
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
- Conditions
- T Acute Lymphoblastic LeukemiaT Lymphoblastic Lymphoma
- Interventions
- Drug: CytarabineDrug: CyclophosphamideDrug: AsparaginaseOther: Laboratory Biomarker AnalysisDrug: Daunorubicin HydrochlorideDrug: Leucovorin CalciumDrug: MethotrexateDrug: MercaptopurineDrug: DexamethasoneDrug: PegaspargaseDrug: Doxorubicin HydrochlorideDrug: PrednisoneDrug: NelarabineDrug: Vincristine SulfateRadiation: Radiation TherapyDrug: Thioguanine
- First Posted Date
- 2006-12-05
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1895
- Registration Number
- NCT00408005
- Locations
- 🇺🇸
Scott and White Memorial Hospital, Temple, Texas, United States
🇺🇸Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer
- Conditions
- Breast CancerMetastatic Breast Cancer
- Interventions
- First Posted Date
- 2006-11-27
- Last Posted Date
- 2017-12-22
- Lead Sponsor
- George Albert Fisher
- Target Recruit Count
- 21
- Registration Number
- NCT00404066
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸Santa Clara Valley Medical Center, San Jose, California, United States
Treatment of Acute Lymphoblastic Leukemia in Children
- Conditions
- Drug/Agent Toxicity by Tissue/OrganLeukemia
- Interventions
- Drug: asparaginaseDrug: cyclophosphamideDrug: cytarabineDrug: dexrazoxane hydrochlorideDrug: dexamethasoneDrug: doxorubicin hydrochlorideDrug: leucovorin calciumDrug: etoposideDrug: mercaptopurineDrug: methotrexateDrug: pegaspargaseDrug: methylprednisoloneDrug: prednisoloneDrug: therapeutic hydrocortisoneDrug: vincristine sulfateRadiation: radiation therapy
- First Posted Date
- 2006-11-17
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 800
- Registration Number
- NCT00400946
- Locations
- 🇨🇦
McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇺🇸Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States
🇨🇦Centre de Recherche du Centre Hospitalier de l'Universite Laval, Sainte Foy, Quebec, Canada
CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors
- Conditions
- Polyarteritis NodosaMicroscopic Polyangiitis
- First Posted Date
- 2006-11-16
- Last Posted Date
- 2006-11-16
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 124
- Registration Number
- NCT00400075
- Locations
- 🇨🇭
Camillo Ribi, Geneva, Switzerland
Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for the Treatment of HER-2/Neu-Overexpressing Metastatic Breast Cancer
- Conditions
- Breast Neoplasms
- Interventions
- Biological: Allogeneic GM-CSF-secreting breast cancer vaccineDrug: TrastuzumabDrug: Cyclophosphamide
- First Posted Date
- 2006-11-15
- Last Posted Date
- 2020-04-22
- Lead Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Target Recruit Count
- 22
- Registration Number
- NCT00399529
- Locations
- 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
CHUSPAN SCS BP Treatment of Churg-Strauss Syndrome Without Poor-Prognosis Factors
- Conditions
- Churg-Strauss Syndrome
- First Posted Date
- 2006-11-14
- Last Posted Date
- 2006-11-14
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 72
- Registration Number
- NCT00399399
- Locations
- 🇨🇭
Camillo Ribi, Geneva, Switzerland
Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2006-11-10
- Last Posted Date
- 2012-08-28
- Lead Sponsor
- Technical University of Munich
- Target Recruit Count
- 12
- Registration Number
- NCT00397800
- Locations
- 🇩🇪
Universitaetsklinkum Magdeburg der Otto-von-Guericke-Universitaet Magdeburg, Magdeburg, Germany
🇩🇪Universitatsklinik Mainz, Mainz, Germany
🇩🇪LMU-Klinikum Grosshadern, Munich, Germany
Combination Chemotherapy in Treating Young Male Patients With Hodgkin's Lymphoma
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2006-11-10
- Last Posted Date
- 2020-03-26
- Lead Sponsor
- Christine Mauz-Körholz
- Target Recruit Count
- 16
- Registration Number
- NCT00398554
- Locations
- 🇨🇭
University Children's Hospital, Zurich, Switzerland
🇩🇪Medizinische Hochschule Hannover, Hannover, Germany
🇩🇪Klinikum Augsburg, Augsburg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.